Tags

Type your tag names separated by a space and hit enter

Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project.
Ann Oncol 2012; 23(5):1320-4AO

Abstract

BACKGROUND

In epidemiological studies, Helicobacter pylori infection is usually detected by enzyme-linked immunosorbent assay (ELISA). However, infection can spontaneously clear from the mucosa during the progression of atrophy and could lead to substantial under-detection of infection and underestimation of its effect on gastric cancer (GC) risk. Antibodies detected by western blot are known to persist longer after the loss of the infection.

METHODS

In a nested case-control study from the Eurogast-EPIC cohort, including 88 noncardia GC cases and 338 controls, we assessed the association between noncardia GC and H. pylori infection comparing antibodies detected by western blot (HELICOBLOT2.1) to those detected by ELISA (Pyloriset EIA-GIII(®)).

RESULTS

By immunoblot, 82 cases (93.2%) were H. pylori positive, 10 of these cases (11.4%) were negative by ELISA and only 6 cases (6.8%) were negative by both ELISA and immunoblot. Multivariable odds ratio (OR) for noncardia GC comparing immunoglobulin G positive versus negative by ELISA was 6.8 [95% confidence interval (CI) 3.0-15.1], and by immunoblot, the OR was 21.4 (95% CI 7.1-64.4).

CONCLUSIONS

Using a western blot assay, nearly all noncardia GC were classified as H. pylori positive and the OR was more than threefold higher than the OR assessed by ELISA, supporting the hypothesis that H. pylori infection is a necessary condition for noncardia GC.

Authors+Show Affiliations

Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, Barcelona, Spain. cagonzalez@iconcologia.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Studies
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21917738

Citation

González, C A., et al. "Helicobacter Pylori Infection Assessed By ELISA and By Immunoblot and Noncardia Gastric Cancer Risk in a Prospective Study: the Eurgast-EPIC Project." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 23, no. 5, 2012, pp. 1320-4.
González CA, Megraud F, Buissonniere A, et al. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. Ann Oncol. 2012;23(5):1320-4.
González, C. A., Megraud, F., Buissonniere, A., Lujan Barroso, L., Agudo, A., Duell, E. J., ... Riboli, E. (2012). Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 23(5), pp. 1320-4. doi:10.1093/annonc/mdr384.
González CA, et al. Helicobacter Pylori Infection Assessed By ELISA and By Immunoblot and Noncardia Gastric Cancer Risk in a Prospective Study: the Eurgast-EPIC Project. Ann Oncol. 2012;23(5):1320-4. PubMed PMID: 21917738.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. AU - González,C A, AU - Megraud,F, AU - Buissonniere,A, AU - Lujan Barroso,L, AU - Agudo,A, AU - Duell,E J, AU - Boutron-Ruault,M C, AU - Clavel-Chapelon,F, AU - Palli,D, AU - Krogh,V, AU - Mattiello,A, AU - Tumino,R, AU - Sacerdote,C, AU - Quirós,J R, AU - Sanchez-Cantalejo,E, AU - Navarro,C, AU - Barricarte,A, AU - Dorronsoro,M, AU - Khaw,K-T, AU - Wareham,N, AU - Allen,N E, AU - Tsilidis,K K, AU - Bas Bueno-de-Mesquita,H, AU - Jeurnink,S M, AU - Numans,M E, AU - Peeters,P H M, AU - Lagiou,P, AU - Valanou,E, AU - Trichopoulou,A, AU - Kaaks,R, AU - Lukanova-McGregor,A, AU - Bergman,M M, AU - Boeing,H, AU - Manjer,J, AU - Lindkvist,B, AU - Stenling,R, AU - Hallmans,G, AU - Mortensen,L M, AU - Overvad,K, AU - Olsen,A, AU - Tjonneland,A, AU - Bakken,K, AU - Dumeaux,V, AU - Lund,E, AU - Jenab,M, AU - Romieu,I, AU - Michaud,D, AU - Mouw,T, AU - Carneiro,F, AU - Fenge,C, AU - Riboli,E, Y1 - 2011/09/14/ PY - 2011/9/16/entrez PY - 2011/9/16/pubmed PY - 2012/9/8/medline SP - 1320 EP - 4 JF - Annals of oncology : official journal of the European Society for Medical Oncology JO - Ann. Oncol. VL - 23 IS - 5 N2 - BACKGROUND: In epidemiological studies, Helicobacter pylori infection is usually detected by enzyme-linked immunosorbent assay (ELISA). However, infection can spontaneously clear from the mucosa during the progression of atrophy and could lead to substantial under-detection of infection and underestimation of its effect on gastric cancer (GC) risk. Antibodies detected by western blot are known to persist longer after the loss of the infection. METHODS: In a nested case-control study from the Eurogast-EPIC cohort, including 88 noncardia GC cases and 338 controls, we assessed the association between noncardia GC and H. pylori infection comparing antibodies detected by western blot (HELICOBLOT2.1) to those detected by ELISA (Pyloriset EIA-GIII(®)). RESULTS: By immunoblot, 82 cases (93.2%) were H. pylori positive, 10 of these cases (11.4%) were negative by ELISA and only 6 cases (6.8%) were negative by both ELISA and immunoblot. Multivariable odds ratio (OR) for noncardia GC comparing immunoglobulin G positive versus negative by ELISA was 6.8 [95% confidence interval (CI) 3.0-15.1], and by immunoblot, the OR was 21.4 (95% CI 7.1-64.4). CONCLUSIONS: Using a western blot assay, nearly all noncardia GC were classified as H. pylori positive and the OR was more than threefold higher than the OR assessed by ELISA, supporting the hypothesis that H. pylori infection is a necessary condition for noncardia GC. SN - 1569-8041 UR - https://www.unboundmedicine.com/medline/citation/21917738/Helicobacter_pylori_infection_assessed_by_ELISA_and_by_immunoblot_and_noncardia_gastric_cancer_risk_in_a_prospective_study:_the_Eurgast_EPIC_project_ L2 - https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdr384 DB - PRIME DP - Unbound Medicine ER -